Zimbabwe Faces New Challenge in HIV Treatment as Resistance to Dolutegravir (DTG)Emerges
Zimbabwe's remarkable progress in HIV treatment faces a new hurdle as cases of resistance to the life-saving drug, Dolutegravir (DTG), emerge. With over 1.2 million people currently on Antiretroviral Therapy (ART), accounting for approximately 90% of those living with HIV, the country's achievements in combating